Olfr561 Inhibitors
Olfr561, an olfactory receptor, plays a crucial role in detecting specific odorant signals, transducing them into cellular responses. Functioning as a G protein-coupled receptor (GPCR), Olfr561 activates intracellular signaling pathways, including the PI3K/Akt, MAPK/ERK, and JAK/STAT pathways. These pathways contribute to the olfactory signal transduction, ultimately leading to the perception of olfactory stimuli. Inhibition of Olfr561 involves targeted modulation of these signaling pathways, either directly through competitive binding or indirectly by influencing broader cellular processes. The inhibition of Olfr561 is achieved through a diverse array of chemicals with distinct mechanisms. For instance, Quinacrine disrupts lysosomal function, affecting Olfr561 expression by interfering with cellular processes. Amiloride, a sodium channel blocker, modulates ion homeostasis, indirectly suppressing Olfr561 expression by altering intracellular ionic balance. Triciribine targets the PI3K/Akt pathway, modulating Olfr561 activity by interfering with downstream effectors crucial for its normal functioning. Thapsigargin disrupts calcium homeostasis, leading to decreased expression and function of Olfr561.
Ruxolitinib influences Olfr561 through the JAK/STAT pathway, providing another avenue for targeted modulation. Forskolin, an adenylyl cyclase activator, indirectly inhibits Olfr561 by stimulating cAMP production. Additionally, inhibitors like Wortmannin, U0126, 2-Deoxy-D-glucose, Cycloheximide, PD98059, and LY294002 target specific signaling pathways (PI3K/Akt, MAPK/ERK, glycolysis, protein synthesis, ERK) associated with Olfr561, altering its expression and function. In conclusion, the intricate network of biochemical events underlying Olfr561's function and inhibition emphasizes the complexity of olfactory signal transduction. Targeted modulation of specific pathways provides valuable insights into understanding olfactory receptor regulation and opens avenues for further research in the field.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $46.00 $57.00 $87.00 $3257.00 $4821.00 | 4 | |
Antimalarial drug inhibiting Olfr561 through interference with lysosomal function. Quinacrine disrupts cellular processes, leading to altered expression and function of Olfr561 as a downstream consequence of lysosomal dysfunction. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker influencing Olfr561 by modulating ion homeostasis. Amiloride disrupts cellular ionic balance, indirectly suppressing Olfr561 expression and signaling by altering the intracellular environment. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor affecting Olfr561 through the PI3K/Akt pathway. Triciribine disrupts the PI3K pathway, modulating Olfr561 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA inhibitor indirectly inhibiting Olfr561. Thapsigargin disrupts calcium homeostasis, modulating olfactory signaling pathways and consequently leading to decreased expression and function of Olfr561. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor influencing Olfr561 through the JAK/STAT pathway. Ruxolitinib disrupts the JAK/STAT signaling cascade, resulting in altered expression and function of Olfr561 as a downstream consequence of pathway inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor influencing Olfr561 through the PI3K/Akt pathway. Wortmannin disrupts the PI3K pathway, modulating Olfr561 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor affecting Olfr561 through the MAPK/ERK pathway. U0126 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr561 as a downstream consequence of pathway inhibition. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Glycolysis inhibitor indirectly influencing Olfr561. 2-Deoxy-D-glucose disrupts cellular energy metabolism, modulating olfactory signaling pathways and leading to suppressed expression and activity of Olfr561. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Protein synthesis inhibitor affecting Olfr561 indirectly. Cycloheximide disrupts translation processes, leading to altered expression and turnover of Olfr561 as a downstream consequence of impaired protein synthesis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
ERK inhibitor influencing Olfr561 through the MAPK/ERK pathway. PD98059 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr561 as a downstream consequence of pathway inhibition. | ||||||